Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco
Apogenix /
Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent
Glioblastoma at Biotech Showcase in San Francisco
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Heidelberg, Germany, Jan. 7, 2014 - Apogenix, a clinical stage biopharmaceutical
company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer,
will present the results of the completed phase II efficacy trial in patients
with recurrent glioblastoma at the Biotech Showcase(TM) in San Francisco. The
presentation will take place on Tuesday, Jan. 14, at 4 p.m. PST at the Parc 55
Wyndham San Francisco - Union Square.
"The results of this controlled phase II trial represent the most important
milestone since Apogenix was founded," said Thomas Hoeger. "We are actively
discussing the further development of APG101 toward approval with the regulatory
authorities."
About Apogenix
Apogenix develops protein therapeutics that could transform the treatment of
life-threatening diseases by targeting critical pathways involved in the growth,
migration, and apoptosis of diseased cells. The company's lead drug candidate
APG101 is currently being evaluated in patients with glioblastoma - a disease
with a tremendous need for new and effective therapies.
About APG101
Apogenix' lead drug candidate APG101 is a fully human fusion protein that
consists of the extracellular domain of the CD95 receptor and the Fc portion of
an IgG antibody. The interaction between the CD95 ligand and the CD95 receptor
activates an intracellular signaling pathway that stimulates the invasive growth
and migration of tumor cells, such as glioblastoma cells. APG101 binds to the
CD95 ligand and thus inhibits activation of the CD95 signaling pathway,
resulting in reduced tumor cell growth and migration.
Contact
Thomas Hoeger, Ph.D., CEO/CFO
Apogenix GmbH
Phone: +49 (6221) 58 60 80
E-Mail: contact@apogenix.com
Web: www.apogenix.com
Media Contacts
USA: Europe:
Martina Schwarzkopf, Ph.D. Raimund Gabriel
Russo Partners, LLC MC Services AG
Phone: +1 (212) 845 4292 Phone: +49 (89) 210 228 30
martina.schwarzkopf@russopartnersllc.com raimund.gabriel@mc-services.eu
Press release (PDF):
http://hugin.info/146079/R/1753017/591200.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Apogenix via GlobeNewswire
[HUG#1753017]
